📣 VC round data is live. Check it out!

4basebio Valuation Multiples

Discover revenue and EBITDA valuation multiples for 4basebio and similar public comparables like Pacific Edge, ArcticZymes, Vitrafy, SDI Group and more.

4basebio Overview

About 4basebio

4basebio PLC is a life sciences group focused on therapeutic DNA for gene therapies and DNA vaccines and providing solutions for effectively and safely delivering these DNA-based products to patients. The company operates across three geographic segments: Europe, the United States, and the Rest of the World, with the majority of its revenue generated from the United States.


Founded

2019

HQ

United Kingdom

Employees

110

Financials (FY)

Revenue: $1M
EBITDA: ($15M)

EV

$70M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

4basebio Financials

4basebio reported last fiscal year revenue of $1M and negative EBITDA of ($15M).

In the same fiscal year, 4basebio generated $854K in gross profit, ($15M) in EBITDA losses, and had net loss of ($17M).


4basebio P&L

In the most recent fiscal year, 4basebio reported revenue of $1M and EBITDA of ($15M).

4basebio is unprofitable as of last fiscal year, with gross margin of 68%, EBITDA margin of (1176%), and net margin of (1322%).

See analyst estimates for 4basebio
Last FY20232024202620272028
Revenue$1M$686K$1M
Gross Profit$854K$461K$854K
Gross Margin68%67%68%
EBITDA($15M)($10M)($15M)
EBITDA Margin(1176%)(1451%)(1176%)
EBIT Margin(1371%)(1614%)(1371%)
Net Profit($17M)($10M)($17M)
Net Margin(1322%)(1515%)(1322%)

Financial data powered by Morningstar, Inc.

4basebio Stock Performance

4basebio has current market cap of $97M, and enterprise value of $70M.

Market Cap Evolution


4basebio's stock price is $6.24.

4basebio share price decreased by 8.5% in the last 30 days, and by 58.0% in the last year.

4basebio has an EPS (earnings per share) of $-1.08.

See more trading valuation data for 4basebio
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$70M$97M-5.2%-8.5%-16.5%-58.0%$-1.08

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

4basebio Valuation Multiples

4basebio trades at 55.6x EV/Revenue multiple, and (4.7x) EV/EBITDA.

See NTM and 2027E valuation multiples for 4basebio

4basebio Financial Valuation Multiples

As of May 9, 2026, 4basebio has market cap of $97M and EV of $70M.

4basebio has a P/E ratio of (5.8x).

Last FY20232024202620272028
EV/Revenue55.6x102.5x55.6x
EV/EBITDA(4.7x)(7.1x)(4.7x)
EV/EBIT(4.1x)(6.3x)(4.1x)
EV/Gross Profit82.3x152.5x82.3x
P/E(5.8x)(9.3x)(5.8x)
EV/FCF(4.2x)(6.8x)(4.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 4basebio Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

4basebio Margins & Growth Rates

In the most recent fiscal year, 4basebio reported gross margin of 68%, EBITDA margin of (1176%), and net margin of (1322%).

See estimated margins and future growth rates for 4basebio

4basebio Margins

Last FY2024202720282029
Gross Margin68%68%
EBITDA Margin(1176%)(1176%)
EBIT Margin(1371%)(1371%)
Net Margin(1322%)(1322%)
FCF Margin(1320%)(1320%)

4basebio Growth Rates

23/2426/2727/2828/29
Revenue Growth84%
Gross Profit Growth85%
EBITDA Growth49%
EBIT Growth57%
Net Profit Growth61%
FCF Growth61%

Data powered by FactSet, Inc. and Morningstar, Inc.

4basebio Operational KPIs

4basebio's revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.2M for the same period.

Access forward-looking KPIs for 4basebio
Last FY20232024202620272028
Revenue per Employee$0.0M
Opex per Employee$0.2M
S&M Expenses to Revenue38%55%38%
G&A Expenses to Revenue151%249%151%
R&D Expenses to Revenue502%704%502%
Opex to Revenue1439%1681%1439%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

4basebio Competitors

4basebio competitors include Pacific Edge, ArcticZymes, Vitrafy, SDI Group, Bioventix, Biohit, Genoway, Bio-Works Technologies, Insight Molecular and AnteoTech.

Most 4basebio public comparables operate across Life Sciences Tools, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Pacific Edge7.2x12.1x(5.0x)(4.4x)
ArcticZymes6.9x6.4x36.2x47.9x
Vitrafy2106.7x85.6x(11.1x)(8.1x)
SDI Group1.7x1.5x9.4x7.8x
Bioventix6.4x6.6x8.2x8.7x
Biohit2.1x2.0x9.6x9.9x
Genoway1.9x1.9x7.9x11.0x
Bio-Works Technologies4.5x(16.9x)

This data is available for Pro users. Sign up to see all 4basebio competitors and their valuation data.

Start Free Trial

4basebio Funding History

Before going public, 4basebio raised $38M in total equity funding, across 1 round.


4basebio Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-24Secondary - publicElevage Medical Technologies; M&G Investments$38M4basebio PLC, an AIM-listed company, announced a strategic investment on July 29, 2024, from Elevage Medical Technologies (a Patient Square Capital platform) and M&G Investment Management Limited (acting on behalf of Prudential Assurance Company). The combined investment consisted of £40 million in new share issuance at £15 per share, with Elevage and M&G acquiring 2,666,667 and 1,961,074 ordinary shares respectively. Following completion, Elevage and M&G together held approximately 29.9% of the company. The transaction also included a secondary purchase of £29.4 million in shares from existing shareholders. 4basebio develops and commercializes large-scale synthetic DNA manufacture and nanoparticle delivery solutions for cell and gene therapies and vaccines. The company reported that 2024 revenues showed a significant step change compared to 2023, with DNA revenues doubling during the 2024 financial year. By the time of this investment, 4basebio had achieved commercial milestones including agreements to supply high-quality and GMP synthetic DNA to tier-one pharmaceutical companies and DNA for mRNA vaccine production.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 4basebio

When was 4basebio founded?4basebio was founded in 2019.
Where is 4basebio headquartered?4basebio is headquartered in United Kingdom.
How many employees does 4basebio have?As of today, 4basebio has over 110 employees.
Who is the CEO of 4basebio?4basebio's CEO is Amy Jo Walker.
Is 4basebio publicly listed?Yes, 4basebio is a public company listed on London Stock Exchange.
What is the stock symbol of 4basebio?4basebio trades under 4BB ticker.
When did 4basebio go public?4basebio went public in 2021.
Who are competitors of 4basebio?4basebio main competitors include Pacific Edge, ArcticZymes, Vitrafy, SDI Group, Bioventix, Biohit, Genoway, Bio-Works Technologies, Insight Molecular, AnteoTech.
What is the current market cap of 4basebio?4basebio's current market cap is $97M.
What is the current revenue of 4basebio?4basebio's last fiscal year revenue is $1M.
What is the current EV/Revenue multiple of 4basebio?Current revenue multiple of 4basebio is 55.6x.
Is 4basebio profitable?No, 4basebio is not profitable.
How many companies 4basebio has acquired to date?4basebio hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies 4basebio has invested to date?4basebio hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 4basebio

Lists including 4basebio

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial